NCT06682780View on ClinicalTrials.gov

A Phase I/II Study of LM-2417 in Subjects With Advanced Solid Tumours

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

320

Participants

Timeline

Start Date

September 17, 2025

Primary Completion Date

December 25, 2028

Study Completion Date

December 1, 2029

Conditions
Advanced Solid Tumor
Interventions
DRUG

LM-2417

Q2W/Q3W,Intravenous Drip

DRUG

Docetaxel

Q3W,Intravenous Drip

DRUG

Toripalimab/Tirelizumab

Q3W,Intravenous Drip

DRUG

Carboplatin

Q3W,Intravenous Drip

DRUG

Niraparib

QD,Oral Administration

DRUG

Lenvatinib

QD,Oral Administration

Trial Locations (1)

Unknown

RECRUITING

FuDan University Shanghai Cancer Center, Shanghai

Sponsors
All Listed Sponsors
lead

LaNova Medicines Limited

INDUSTRY

NCT06682780 - A Phase I/II Study of LM-2417 in Subjects With Advanced Solid Tumours | Biotech Hunter | Biotech Hunter